Newsroom | 43581 results
Sorted by: Latest
-
Fortis Healthcare remporte six distinctions de premier plan au sommet FICCI Advantage Healthcare India 2026 et renforce le leadership médical mondial de l'Inde
NEW DELHI--(BUSINESS WIRE)--Fortis Healthcare vient de recevoir six prix prestigieux au FICCI Advantage Healthcare India 2026, le sommet international sur les voyages médicaux , soulignant son leadership et son excellence dans la prestation de soins de santé à l'échelle mondiale. Ces distinctions, présentées lors du sommet de trois jours qui s’est tenu du 23 au 25 février 2026 dans le cadre des FICCI Medical Value Travel Awards, consolident la réputation de Fortis en tant que partenaire de conf...
-
LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions
MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma to Present 17 Scientific Abstracts at AAD 2026...
-
Health Gorilla and GuardDog Telehealth Set the Record Straight
CORAL GABLES, Fla.--(BUSINESS WIRE)--Health Gorilla today released materials demonstrating that GuardDog always represented to Health Gorilla that its services were for treatment purposes. The materials in question are a 2025 case study that GuardDog developed with Health Gorilla which was meant to be released for marketing purposes for both companies. The case study reflects GuardDog’s continuing description over a period of years that its services were for treatment purposes, because it repre...
-
Medifast Announces Cooperation Agreement with Steamboat Capital
BALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company’s 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperati...
-
HealthWarehouse.com Reports Full Year 2025 Results
CINCINNATI--(BUSINESS WIRE)--HealthWarehouse.com reported 2025 net sales of $49.0 million, a 46% increase over 2024, as partner services prescription revenues increased 87%....
-
Sakura Finetek Global and Hamamatsu Photonics K.K. Global Alliance Press Release
TORRANCE, Calif.--(BUSINESS WIRE)--A new global Alliance between Hamamatsu Photonics K.K and Sakura Finetek Global...
-
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of th...
-
Fortis Healthcare Wins Six Top Honours at FICCI Advantage Healthcare India 2026; Strengthening India’s Global Medical Leadership
NEW DELHI--(BUSINESS WIRE)--Fortis Healthcare has been honored with six prestigious awards at the FICCI Advantage Healthcare India, International Summit on Medical Value Travel....
-
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST. Dividend proposal The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contribution...
-
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray
CRYSTAL LAKE, Ill,--(BUSINESS WIRE)--Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray...